Literature DB >> 12358740

Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice.

Laurel M Bolin1, Iwona Strycharska-Orczyk, Richard Murray, J William Langston, Donato Di Monte.   

Abstract

To test the hypothesis that neuroinflammation contributes to dopaminergic neuron death in the MPTP-lesioned mouse, we compared nigrostriatal degeneration in interleukin (IL)-6 (+/+) with IL-6 (-/-) mice. In the absence of IL-6, a single injection of MPTP (30 mg/kg) resulted in significantly greater striatal dopamine depletion than that measured in IL-6 (+/+) mice. The observed dopamine depletion was MPTP dose dependent. This loss of striatal dopamine and a significantly greater loss of TH+ cells in the substantia nigra pars compacta in IL-6 (-/-) mice as compared with control IL-6 (+/+) mice, suggest that IL-6 is neuroprotective in the MPTP-lesioned nigrostriatal system. Co-localization experiments identified striatal astrocytes as the source of IL-6 in IL-6 (+/+) mice at 1 and 7 days postinjection of MPTP. The increased sensitivity of dopaminergic neurons to neurotoxicant in the absence of IL-6, is compatible with a neuroprotective activity of IL-6 in the injured nigrostriatal system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358740     DOI: 10.1046/j.1471-4159.2002.01131.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  27 in total

1.  IL6 protects MN9D cells and midbrain dopaminergic neurons from MPP+-induced neurodegeneration.

Authors:  Björn Spittau; Xiaolai Zhou; Ming Ming; Kerstin Krieglstein
Journal:  Neuromolecular Med       Date:  2012-07-08       Impact factor: 3.843

Review 2.  Gender differences in neurological disease: role of estrogens and cytokines.

Authors:  Anna Członkowska; Agnieszka Ciesielska; Grazyna Gromadzka; Iwona Kurkowska-Jastrzebska
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

3.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

4.  Lipopolysaccharide-Induced Microglia Activation Promotes the Survival of Midbrain Dopaminergic Neurons In Vitro.

Authors:  Xiaolai Zhou; Björn Spittau
Journal:  Neurotox Res       Date:  2017-11-29       Impact factor: 3.911

Review 5.  Critical Roles of Glutaredoxin in Brain Cells-Implications for Parkinson's Disease.

Authors:  Olga Gorelenkova Miller; John J Mieyal
Journal:  Antioxid Redox Signal       Date:  2018-01-05       Impact factor: 8.401

Review 6.  Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.

Authors:  Bin Liu
Journal:  AAPS J       Date:  2006-09-29       Impact factor: 4.009

7.  Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.

Authors:  Kathryn Lanza; Amy E Perkins; Terrence Deak; Christopher Bishop
Journal:  Neurobiol Aging       Date:  2019-05-31       Impact factor: 4.673

8.  Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.

Authors:  Vivian P Chou; Novie Ko; Theodore R Holman; Amy B Manning-Boğ
Journal:  J Vis Exp       Date:  2014-01-07       Impact factor: 1.355

9.  Immunity and inflammation in neurodegenerative diseases.

Authors:  Giuseppe Cappellano; Miryam Carecchio; Thomas Fleetwood; Luca Magistrelli; Roberto Cantello; Umberto Dianzani; Cristoforo Comi
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

10.  Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice.

Authors:  Tcs Costa; E Fernandez-Villalba; V Izura; A M Lucas-Ochoa; N J Menezes-Filho; R C Santana; M D de Oliveira; F M Araújo; C Estrada; Vda Silva; S L Costa; M T Herrero
Journal:  J Neuroimmune Pharmacol       Date:  2020-06-21       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.